Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tuan Hoang-Xuan

Dermatology Chino, CA Doctor of Osteopathy

NPI 1760448302 CMS profile 79201

13768 Roswell Ave, Suite 102, Chino, CA 91710

Open in the dashboard

General payments

$2,967

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tuan Hoang-Xuan of Chino, CA is reported in the CMS Open Payments database as having received $2,967 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $643 28
2024 General $944 46
2023 General $448 22
2022 General $548 33
2021 General $134 8
2020 General $42 2
2019 General $209 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tuan Hoang-Xuan
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Tuan Hoang-Xuan were reported at $643. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Tuan Hoang-Xuan Dermatology median Middle half National median
2019 $209 $454 $129–$1,240 $163
2020 $42 $235 $81–$756 $114
2021 $134 $377 $108–$1,108 $132
2022 $548 $514 $143–$1,391 $149
2023 $448 $607 $159–$1,674 $160
2024 $944 $751 $204–$1,903 $164
2025 $643 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $714 39 payments
  2. LEO Pharma Inc. $669 58 payments
  3. Janssen Biotech, Inc. $471 9 payments
  4. Sun Pharmaceutical Industries Inc. $304 8 payments
  5. Novartis Pharmaceuticals Corporation $224 8 payments
  6. AbbVie, Inc. $109 5 payments
  7. Arcutis Biotherapeutics, Inc. $104 4 payments
  8. Galderma Laboratories, L.P. $95 5 payments
  9. Stemline Therapeutics Inc. $86 1 payment
  10. E.R. Squibb & Sons, L.L.C. $76 2 payments
  11. Other $115 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,478 141 payments
  2. Education $489 5 payments
Products named General payments · program years 2019–2025
  1. ADBRY $643 57 payments
  2. CIBINQO $468 29 payments
  3. TREMFYA $440 7 payments
  4. LITFULO $347 20 payments
  5. EUCRISA $287 17 payments
  6. ILUMYA $209 7 payments
  7. COSENTYX $123 4 payments
  8. Zoryve $104 4 payments
  9. ELZONRIS $86 1 payment
  10. SOTYKTU $76 2 payments
  11. Other $676 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

910

Median for Dermatology: 534

Drug cost

$17,575

Median for Dermatology: $67,151

Branded share of claims

4.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 112 $2,758
Minocycline Hcl Generic 85 $2,755
Doxepin Hcl Generic 76 $2,352
Fluocinonide Generic 49 $2,006
Betamethasone Dipropionate Generic 23 $1,746
Mupirocin Generic 206 $1,254
Ketoconazole Generic 56 $1,206
Cefuroxime Cefuroxime Axetil Brand 41 $835
Triamcinolone Acetonide Generic 104 $768
Hydroxyzine Hcl Generic 60 $604

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$190,597

Of which drugs: $226

Medicare patients

358

Average age 73

Services billed

1,907

159 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 43%
Diabetes 32%
Ischemic heart disease 24%
Chronic kidney disease 22%
Depression 16%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 289 $225

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $178
$178 — —
TREMFYA
  • Janssen Biotech, Inc. $145
$145 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $107
$107 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $76
$76 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record